Rubicon Research informs about outcome of board meeting

03 Feb 2026 Evaluate
Rubicon Research has informed that the Board of Directors of the Company at its meeting held today February 3, 2026: On the recommendation of the Nomination and Remuneration Committee, approved the appointment of Pradnya Saravade (DIN: 08472973) as Additional - Independent Woman Director of the Company for a period of three consecutive years effective from February 3, 2026, to February 2, 2029, subject to approval of the members of the Company; Noted the resignation of Anand Agarwal (DIN: 06481297), as a Non-Executive Director - Nominated by General Atlantic Singapore RR, effective from the close of business on February 3, 2026. Copy of the letter received from Anand Agarwal is attached; On the recommendation of the Audit Committee, approved and recommended the appointment of BNP & Associates, Practicing Company Secretaries, a peer reviewed firm (firm Registration No. P2014MH037400), as the Secretarial Auditor of the Company for an immediate term i.e., FY 2025-26 and for the remaining four years of the first five-year term from FY 2026-27 till FY 2029-30, subject to approval of members of the Company; Granted in-principle approval for the merger of KIA Health Tech, wholly owned subsidiary of the Company, with Rubicon Research Limited and their shareholders.

The above information is a part of company’s filings submitted to BSE.

Rubicon Research Share Price

723.25 35.15 (5.11%)
03-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Wework India Managem 581.25
Rubicon Research 723.25
Amagi Media Labs 380.20
Aegis Vopak Terminal 223.00
Mallcom 1175.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×